Medications like Wegovy and Ozempic have gained popularity for their weight loss benefits, but a recent study published in JAMA Network Open revealed that the results may vary for different individuals. Contrary to previous clinical trials that showed significant weight loss of up to 20 percent on semaglutide medications, the new research found that, on average, patients who took these medications only lost 5.1 percent of their body weight. Lead study author Hamlet Gasoyan, PhD, emphasized that while some may have high expectations for substantial weight loss with these medications, the reality may be different.
The study, which analyzed medical records of nearly 3,500 patients with obesity who were prescribed semaglutide or liraglutide, found that patients lost an average of 3.7 percent of their body weight after a year. Specifically, those who took semaglutide lost 5.1 percent of their body weight, while liraglutide users lost 2.2 percent. Interestingly, individuals who took these medications for obesity experienced greater weight loss compared to those who used them for type 2 diabetes. Women, in particular, were more likely to lose weight during the study than men.
Lead study author Hamlet Gasoyan, PhD, from the Cleveland Clinic, along with experts like Mir Ali, MD, and Kunal Shah, MD, shed light on the findings of the study. Dr. Ali, a bariatric surgeon, highlighted that women were 57 percent more likely to lose 10 percent or more of their body weight after a year, indicating that women may experience more significant weight loss on Ozempic and other semaglutides compared to men.
Dr. Shah, an assistant professor in endocrinology, echoed these findings, stating that in practice and previous studies, women tend to lose more weight than men on semaglutide medications. However, Dr. Ali cautioned that individual results may vary, as he has seen both women and men achieve successful weight loss outcomes with these medications.
The reasons behind why women may lose more weight on Ozempic are not entirely clear. Dr. Gasoyan suggested that hormones could play a role in this discrepancy, as these medications are hormone analogues that may be more responsive in women. Additionally, women generally have smaller body mass compared to men, making the medications potentially more effective for them.
Before considering Ozempic or similar medications for weight loss, there are important factors to contemplate. Dr. Shah emphasized the significance of insurance coverage, as these are long-term medications that can be costly. Individuals with underlying gastrointestinal conditions like irritable bowel syndrome should be cautious, as these medications can exacerbate such conditions. Moreover, one must meet the criteria for obesity to be eligible for these medications. Dr. Ali stressed the importance of incorporating lifestyle changes alongside medication use to ensure long-term success in weight management.
In conclusion, while Ozempic and other semaglutides have shown promise in promoting weight loss, individual experiences may vary. Women, in particular, may experience more significant weight loss on these medications, but results are not guaranteed. It is essential to consider various factors before embarking on a weight loss journey with these medications, including insurance coverage, potential side effects, and lifestyle modifications. Ultimately, a holistic approach that combines medication with healthy habits is key to achieving and maintaining weight loss success.
